GRCE
Grace Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-07
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.06
P/S
0.00
EV/EBITDA
-5.00
DCF Value
$1.29
FCF Yield
-17.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-10.6%
ROA
-10.0%
ROIC
-15.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-3.2M | $-0.19 |
| Q2 2026 | $0.00 | $-938.0K | $-0.06 |
| Q1 2026 | $0.00 | $-3.4M | $-0.21 |
| Q4 2025 | $0.00 | $636.0K | $0.05 |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.69
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.